MAPT and Alzheimer disease: Additional challenges with the approaches based on plasma Aβ and Tau include challenges in establishing reference ranges and measures becoming elevated for reasons other than AD, including common comorbidities such as prior myocardial infarction, stroke, or chronic kidney disease [14,23,24].